Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation (Narrative) (Details)

v2.4.0.8
Basis of Presentation (Narrative) (Details) (USD $)
Share data in Millions, unless otherwise specified
3 Months Ended 9 Months Ended 9 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 9 Months Ended 12 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2014
storage_location
drug
Sep. 30, 2013
Sep. 30, 2014
segment
storage_location
drug
Sep. 30, 2013
Dec. 31, 2013
Sep. 30, 2014
Equipment
Minimum
Sep. 30, 2014
Equipment
Maximum
Apr. 30, 2013
Royalty Stream and Milestone Payments Purchase Agreement with Selexis
program
Sep. 30, 2014
Cydex Pharmaceuticals, Inc
Sep. 30, 2013
Cydex Pharmaceuticals, Inc
Sep. 30, 2014
Cydex Pharmaceuticals, Inc
Sep. 30, 2013
Cydex Pharmaceuticals, Inc
Dec. 31, 2013
Cydex Pharmaceuticals, Inc
Jan. 31, 2011
Cydex Pharmaceuticals, Inc
Jan. 31, 2012
Cydex Pharmaceuticals, Inc
Guaranteed Payment
Sep. 30, 2014
Cydex Pharmaceuticals, Inc
Revenue Sharing
Sep. 30, 2013
Cydex Pharmaceuticals, Inc
Revenue Sharing
Sep. 30, 2014
Cydex Pharmaceuticals, Inc
Revenue Sharing
Sep. 30, 2013
Cydex Pharmaceuticals, Inc
Revenue Sharing
Sep. 30, 2014
Cydex Pharmaceuticals, Inc
Other Contingency Payment
Sep. 30, 2013
Cydex Pharmaceuticals, Inc
Other Contingency Payment
Sep. 30, 2014
Cydex Pharmaceuticals, Inc
Other Contingency Payment
Sep. 30, 2013
Cydex Pharmaceuticals, Inc
Other Contingency Payment
Jan. 31, 2010
Metabasis Therapeutics
right
Sep. 30, 2014
Metabasis Therapeutics
Sep. 30, 2013
Metabasis Therapeutics
Sep. 30, 2014
Metabasis Therapeutics
Sep. 30, 2013
Metabasis Therapeutics
Dec. 31, 2013
Metabasis Therapeutics
Sep. 30, 2014
Accounts Receivable
Customer Concentration Risk
customer
Dec. 31, 2013
Accounts Receivable
Customer Concentration Risk
customer
Sep. 30, 2014
Acquired In Process Research And Development
Sep. 30, 2013
Acquired In Process Research And Development
Sep. 30, 2014
Acquired In Process Research And Development
Sep. 30, 2014
Omthera Pharmaceuticals
Sep. 30, 2014
Viking
Property, Plant and Equipment [Line Items]                                                                        
Accumulated deficit $ 666,371,000   $ 666,371,000   $ 671,339,000                                                              
Working capital 180,100,000   180,100,000                                                                  
Earnings (Loss) Per Share                                                                        
Common shares excluded from computation     5.0 0.9                                                                
Cash, Cash Equivalents and Short-term Investments                                                                        
Maturity period of cash and cash equivalents, maximum     3 months                                                                  
Maturity period of short term investments, minimum     3 months                                                                  
Concentrations of Credit Risk                                                                        
Cash deposits 92,800,000   92,800,000   11,100,000                                                              
Concentration risk, number of customers                                                           1 2          
Concentration risk, percentage of accounts receivable                                                           57.00% 75.00%          
Product Shelf Life     5 years                                                                  
Number of Storage Locations 3   3                                                                  
Property and Equipment                                                                        
Estimated useful life of assets           3 years 10 years                                                          
Depreciation 100,000 200,000 100,000 200,000                                                                
Goodwill and Other Identifiable Intangible Assets                                                                        
Finite-lived intangible asset, useful life     20 years                                                                  
Amortization expense 600,000   1,800,000                                                                  
Amortization Expense                                                                        
Amortization expense 2014 2,400,000   2,400,000                                                                  
Amortization expense 2015 2,400,000   2,400,000                                                                  
Amortization expense 2016 2,400,000   2,400,000                                                                  
Amortization expense 2017 2,400,000   2,400,000                                                                  
Amortization expense 2018 2,400,000   2,400,000                                                                  
Acquired In-Process Research and Development                                                                        
Impairment of in-process research and development 0 0 0 480,000                                                       0 0 0    
Gain on write-off of assets     (16,000) 0               500,000                                                
Commercial License Rights                                                                        
Number of commercial license agreement programs               15                                                        
Purchase price               4,600,000                                                        
Payments to acquire intangible assets               3,600,000                                                        
Cash payment due on first anniversary of the closing               1,000,000                                                        
Contingent Liabilities                                                                        
Contingent liability                           17,600,000                                            
Purchase of commercial license rights                             4,300,000 0 0 1,600,000 0 300,000 100,000 300,000 100,000                          
Fair value of liability                 12,900,000   12,900,000   9,300,000                       3,500,000   3,500,000   4,200,000              
Contingent liability change in amount                 2,800,000 (1,200,000) 5,600,000 2,100,000                         1,200,000 700,000 (700,000) (1,700,000)                
Number of contingent value rights                                               4                        
Number of contingent value rights per series of contingent value rights                                               1                        
Number of contingent value rights issued for each share                                               4                        
Contingent value rights, frequency of cash payment                                               6 months                        
Revenue Recognition                                                                        
Period allowed for return of products, minimum     30 days                                                                  
Period allowed for return of products, maximum     90 days                                                                  
Allowance for Doubtful Accounts                                                                        
Accounts receivable outstanding considered past due after period, minimum     30 days                                                                  
Accounts receivable outstanding considered past due after period, maximum     90 days                                                                  
Allowance for doubtful accounts 0   0   0                                                              
Sale of Royalty Rights                                                                        
Deferred revenue 0   0   100,000                                                              
Milestone Payments                                                                        
Event-based payment                                                                     1,000,000  
Discontinued Operations                                                                        
Number of drugs included in product line 4   4                                                                  
Gain on sale of Avinza Product Line before income taxes 0 0 0 2,588,000                                                                
Segment Reporting                                                                        
Number of reportable segments     2                                                                  
Assets 272,283,000   272,283,000   104,713,000                                                             2,943,000
Liabilities $ 229,500,000   $ 229,500,000   $ 55,100,000                                                             $ 4,532,000